

Handwritten signature/initials.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/973,105	10/09/2001	Jeffrey H. Baxter	6815.US.01	5606
25755	7590	05/23/2005	EXAMINER	
ROSS PRODUCTS DIVISION OF ABBOTT LABORATORIES DEPARTMENT 108140-DS/1 625 CLEVELAND AVENUE COLUMBUS, OH 43215-1724			GHALI, ISIS A D	
			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 05/23/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/973,105

Applicant(s)

BAXTER, JEFFREY H.

Examiner

Isis Ghali

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 31 January 1995.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1 and 3-43 is/are pending in the application.
- 4a) Of the above claim(s) 7-43 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1 and 3-6 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>2/12/02</u> . | 6) <input type="checkbox"/> Other: _____ |

PD

DETAILED ACTION

The receipt is acknowledged of applicant's amendment, filed 01/31/2005.

Claim 2 has been canceled; claims 7-43 are withdrawn from consideration.

Claims 1, 3-6 are included in the prosecution.

1. This application contains claims 7-43 drawn to an invention nonelected with traverse. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

The standing rejections:

2. Claims 1 and 6 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 10101576 ('576).

3. Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,462,924 ('924) in view of US 4,994,457 ('457).

Response to Arguments

4. Applicant's arguments filed 03/12/2004 have been fully considered but they are not persuasive.

Applicant traverse the rejection of claims 1 and 6 as being anticipated by JP '576 by arguing that the reference does not teach glutamine to treat digestive disorders by itself, the reference teaches glutamine effective in combination with other ingredients.

In response to this argument, the examiner is pointing out to the scope of the rejected claims, which is "method for providing glutamine", and the reference disclosed providing acetyl glutamine to treat digestive organ diseases, i.e. for the same reason claimed by applicant in claim 6. The claim language does not exclude the presence of other ingredients, active or inactive, even in major amounts. Therefore, the limitations of the rejected claims are met by JP '576.

Applicant traverse the rejection of claims 1-6 over US '924 in view of US '457 by arguing that US '924 teaches parenteral administration of n-acetyl L-glutamine with fatty acids. US '457 does not teach the bioavailability of NAQ salts in the intestine or address deficiencies of US '924. No motivation to combine the references.

In response to these argument, the examiner position is the primary reference teaches oral supplementation of glutamine to the control group (col.4, lines 49-50, 59) to treat diseases of intestinal mucosa, therefore, the art recognized the administration of glutamine orally. Note the scope of the claims is "method for providing glutamine". The claim language does not exclude the presence of other ingredients such as fatty acids, active or inactive, even in major amounts. US '457 is relied upon for the solely teaching of the sodium and potassium salts of glutamine to be known in the art as acceptable salts for oral administration (col.2, lines 44-46). Therefore, US '457 teaches the missing

Art Unit: 1615

teaching from US '924, which is the salts of the glutamine, and the reference does not need to teach the bioavailability of NAQ. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, one having ordinary skill in the art would have been used the sodium and calcium salts of N-acetyl L-glutamine for oral administration motivated by the teaching of US '457 that these salts of glutamine have ulcer inhibiting and anti-irritant effect on the gastric mucosa (col.2, lines 19-23), with reasonable expectation of having non-irritant glutamine supplementation.

Conclusion

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis Ghali whose telephone number is (571) 272-0595. The examiner can normally be reached on Monday-Thursday, 7:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Isis Ghali
Examiner
Art Unit 1615

IG


THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600